Opus Genetics (NASDAQ:IRD) Now Covered by Analysts at Citizens Jmp

Equities research analysts at Citizens Jmp assumed coverage on shares of Opus Genetics (NASDAQ:IRD) in a research report issued to clients and investors on Tuesday. The brokerage set a “market perform” rating and a $12.00 price target on the stock. Citizens Jmp’s target price indicates a potential upside of 134.38% from the stock’s previous close.

Other equities analysts have also issued reports about the stock. Wedbush raised their target price on shares of Opus Genetics from $8.00 to $10.00 and gave the stock an “outperform” rating in a research report on Thursday, March 12th. Cantor Fitzgerald started coverage on shares of Opus Genetics in a research report on Monday, March 30th. They issued an “overweight” rating and a $15.00 price objective on the stock. Lifesci Capital raised Opus Genetics to a “strong-buy” rating in a report on Thursday, February 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of Opus Genetics in a report on Tuesday, April 21st. Finally, Chardan Capital raised their target price on Opus Genetics from $9.00 to $11.00 and gave the company a “buy” rating in a report on Thursday, March 12th. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Opus Genetics currently has an average rating of “Moderate Buy” and an average target price of $10.30.

Opus Genetics Stock Performance

IRD stock opened at $5.12 on Tuesday. The company’s 50 day moving average price is $4.70 and its 200 day moving average price is $3.09. Opus Genetics has a fifty-two week low of $0.81 and a fifty-two week high of $5.81. The firm has a market capitalization of $365.57 million, a price-to-earnings ratio of -6.24 and a beta of 0.52.

Insider Transactions at Opus Genetics

In other news, President Benjamin R. Yerxa sold 7,470 shares of Opus Genetics stock in a transaction on Thursday, April 23rd. The stock was sold at an average price of $5.24, for a total transaction of $39,142.80. Following the completion of the transaction, the president owned 711,535 shares of the company’s stock, valued at $3,728,443.40. The trade was a 1.04% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Robert E. Gagnon sold 7,842 shares of Opus Genetics stock in a transaction dated Thursday, April 23rd. The stock was sold at an average price of $5.18, for a total value of $40,621.56. Following the sale, the chief financial officer owned 592,158 shares of the company’s stock, valued at approximately $3,067,378.44. This represents a 1.31% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders sold 73,395 shares of company stock worth $382,278. Corporate insiders own 11.70% of the company’s stock.

Institutional Trading of Opus Genetics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Nantahala Capital Management LLC increased its position in Opus Genetics by 42.9% during the 4th quarter. Nantahala Capital Management LLC now owns 4,781,330 shares of the company’s stock worth $9,610,000 after purchasing an additional 1,435,407 shares in the last quarter. Balyasny Asset Management L.P. purchased a new stake in Opus Genetics during the 4th quarter worth about $5,463,000. Millennium Management LLC purchased a new stake in Opus Genetics during the 4th quarter worth about $4,025,000. Mink Brook Asset Management LLC increased its position in Opus Genetics by 34.5% during the 4th quarter. Mink Brook Asset Management LLC now owns 1,665,631 shares of the company’s stock worth $3,348,000 after purchasing an additional 427,684 shares in the last quarter. Finally, Vanguard Group Inc. increased its position in Opus Genetics by 35.3% during the 3rd quarter. Vanguard Group Inc. now owns 1,342,025 shares of the company’s stock worth $2,214,000 after purchasing an additional 349,825 shares in the last quarter. Hedge funds and other institutional investors own 14.97% of the company’s stock.

Key Stories Impacting Opus Genetics

Here are the key news stories impacting Opus Genetics this week:

• Positive Sentiment: Analyst interest remains constructive: recent coverage includes Oppenheimer initiating with an “Outperform” and Chardan raising its price target (and other firms issuing Buy/Strong-Buy views), which supports a higher medium-term valuation for IRD.
• Neutral Sentiment: Opus announced management will participate in several leading ophthalmology and industry conferences in May 2026 — helps maintain investor/researcher visibility but is not an immediate clinical readout or revenue catalyst. Company conference participation
• Neutral Sentiment: Small institutional purchases and modest position changes were reported recently (new small stakes and a few increases by advisers); institutional ownership remains below major-cap levels, so flows may not strongly move the stock in either direction.
• Negative Sentiment: Clustered insider selling: several executives (CEO George Magrath, CFO Robert Gagnon, COO Joseph Schachle, President Benjamin Yerxa and others) disclosed sales on April 23rd totaling tens of thousands of shares at roughly $5.18–$5.24 per share. The company says these sales were to cover tax withholding on vested awards, but the concentrated timing likely exerted downward pressure on the share price today. Example filings: CEO form 4 and other SEC disclosures. CEO Form 4 InsiderTrades summary

Opus Genetics Company Profile

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.